Related Experiment Video
Updated: Nov 4, 2025

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma
Hai-Feng Zhang1,2, Christopher S Hughes1,2, Wei Li3
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract:
Cancer cells must overcome anoikis (detachment-induced death) to successfully metastasize. Using proteomic screens, we found that distinct oncoproteins upregulate IL1 receptor accessory protein (IL1RAP) to suppress anoikis. IL1RAP is directly induced by oncogenic fusions of Ewing sarcoma, a highly metastatic childhood sarcoma. IL1RAP inactivation triggers anoikis and impedes metastatic dissemination of Ewing sarcoma cells. Mechanistically, IL1RAP binds the cell-surface system Xc - transporter to enhance exogenous cystine uptake, thereby replenishing cysteine and the glutathione antioxidant. Under cystine depletion, IL1RAP induces cystathionine gamma lyase (CTH) to activate the transsulfuration pathway for de novo cysteine synthesis. Therefore, IL1RAP maintains cyst(e)ine and glutathione pools, which are vital for redox homeostasis and anoikis resistance. IL1RAP is minimally expressed in pediatric and adult normal tissues, and human anti-IL1RAP antibodies induce potent antibody-dependent cellular cytotoxicity of Ewing sarcoma cells. Therefore, we define IL1RAP as a new cell-surface target in Ewing sarcoma, which is potentially exploitable for immunotherapy. SIGNIFICANCE: Here, we identify cell-surface protein IL1RAP as a key driver of metastasis in Ewing sarcoma, a highly aggressive childhood sarcoma. Minimal expression in pediatric and adult normal tissues nominates IL1RAP as a promising target for immunotherapy.See related commentary by Yoon and DeNicola, p. 2679.This article is highlighted in the In This Issue feature, p. 2659.
Insights
Interleukin-1 receptor accessory protein (IL1RAP) helps Ewing sarcoma cells survive detachment and spread. Targeting IL1RAP may offer a new immunotherapy approach for this childhood cancer.
Area of Science:
- Oncology
- Cell Biology
- Cancer Metastasis
Background:
- Metastasis requires cancer cells to evade anoikis, or detachment-induced cell death.
- Oncoproteins can drive metastasis by suppressing anoikis.
- Ewing sarcoma is a highly metastatic childhood cancer.
Purpose of the Study:
- Identify mechanisms by which Ewing sarcoma cells overcome anoikis.
- Determine the role of IL1RAP in Ewing sarcoma metastasis.
- Evaluate IL1RAP as a potential therapeutic target.
Main Methods:
- Proteomic screening to identify anoikis suppressors.
- Investigating IL1RAP function in Ewing sarcoma cell lines.
- Assessing the impact of IL1RAP inactivation on metastasis.
- Analyzing IL1RAP expression in normal and tumor tissues.
- Evaluating anti-IL1RAP antibody efficacy in vitro.
Main Results:
- Distinct oncoproteins upregulate IL1RAP to suppress anoikis.
- IL1RAP is induced by oncogenic fusions in Ewing sarcoma.
- IL1RAP inactivation triggers anoikis and impedes metastasis.
- IL1RAP maintains redox homeostasis by regulating cyst(e)ine and glutathione levels.
- IL1RAP is minimally expressed in normal tissues.
Conclusions:
- IL1RAP is a key driver of anoikis resistance and metastasis in Ewing sarcoma.
- IL1RAP supports cancer cell survival by maintaining redox balance.
- IL1RAP is a promising cell-surface target for Ewing sarcoma immunotherapy.

